论文部分内容阅读
Objective Metformin, a classical and safe anti-diabetic agent, was demonstrated to exert anti-mitogenic effect on anaplastic thyroid carcinoma (ATC) cells and amplify the anti-mitogenic effect of chemotherapeutic agents as doxorubicin and cisplatin.The multi-kinase inhibitor sorafenib is a promising option for treating aggressive and resistant cancer including anaplasticthyroid carcinoma.